Clinical trial

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

NCT03035032

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-23

PhasePHASE4

Study timeline

Study start (actual)2017-06-23Date precision: day

Registry last updated2024-11-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

LeuprolideDRUG · verified · RxNorm: leuprolide

Sponsors & collaborators

Astellas Pharma Singapore Pte. Ltd.lead sponsor

Mapped research locations

SingaporeSingapore3 TaichungTaiwan2 Hong KongHong Kong2 TaipeiTaiwan1 BangkokThailand1 Kuala LumpurMalaysia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03035032 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.